Intergen(R) Company to Market Martek's Fluorescent Proteins
PURCHASE, N.Y., Feb. 3 /PRNewswire/ -- Intergen(R) Company today announced that as of January 30, 1998 it has entered
into an agreement with Martek Biosciences Corporation [Nasdaq:MATK - news] in which Intergen will be the exclusive marketer
and distributor of Martek's fluorescent phycobiliproteins and conjugates.
These phycobiliproteins are individual algal proteins that have a fluorescent power of up to 1O times that of fluorescein, the most
common fluorescent marker. Many of these proteins have the added advantage of being one fifth the size of phycobiliproteins,
which should allow researchers to examine intracellular events. The products have been designed for use in a wide array of
diagnostic and research applications including immunodiagnostics, flow cytometry, genetic testing, immunofluorescence and
imaging technologies.
Mr. Robert Beckman, President and CEO of Intergen Company, said, ''Intergen expects these exciting molecules to find many
new applications in diagnostics and biotechnology, particularly in the search for active compounds in the pharmaceutical industry.''
''This arrangement with Intergen marks Martek's formal entry into the market for fluorescent markers,'' said Henry ''Pete''
Linsert, Jr., Martek's Chairman and CEO. ''The research community is seeking alternatives to current radioactive markers, the
complexity of chemiluminescence, and dimmer fluorescent markers. These initial products along with soon to be introduced
proprietary fluorescent marker products should address those needs.''
Intergen is a leading manufacturer of products that are critical to the commercial development of life sciences into
biopharmaceuticals and diagnostics.
The company was founded in 1987 and has developed a significant market presence through the international commercialization of
its products and through strategic acquisitions.
Intergen products are found as components of a wide variety of innovative biotechnology drugs and diagnostics ranging from
cancer therapeutics to cardiovascular drugs and immunoassays for infectious diseases. Through its focus on life sciences, the
company is a vital partner to its biotechnology customers in providing keys to the development and manufacture of innovative
products.
Headquartered in Purchase, New York, Intergen maintains global operations with facilities in the United States, Canada and the
United Kingdom as well as partnerships in Japan.
SOURCE: Intergen Company |
